Search results for " Recurrence"

showing 10 items of 534 documents

Oncologic outcome and continence recovery after laparoscopic radical prostatectomy: 3 years' follow-up in a "second generation center".

2006

Objectiues: Laparoscopic radical prostatectomy in major centers guarantees oncologic and functional results equal to open procedures. In our institution this operation was introduced in 2001 after an adequate training in laparoscopic surgery. We report the oncologic and functional results after 3 years of experience.Methods: We considered our first 150 patients that had undergone transperitoneal laparoscopic radical prostatectomy. The following parameters were prospectively collected and analyzed: pathological findings, surgical margins, surgical time, blood loss, hospital stay, catheterization, complications, oncologic follow-up and continence.Results: Single positive surgical margins were…

NephrologyLaparoscopic surgeryAdultMalemedicine.medical_specialtySurgical marginTime FactorsLaparoscopic radical prostatectomyTime FactorUrologymedicine.medical_treatmentBiopsyFollow-Up StudieSurgical marginRetrospective StudieInternal medicineContinencemedicineHumansLaparoscopyRetrospective StudiesAgedProstatectomyProstate cancermedicine.diagnostic_testbusiness.industryProstatectomySurgical marginsIncidenceProstatic NeoplasmsRecovery of FunctionMiddle AgedEndoscopySurgeryTreatment OutcomeUrinary IncontinenceProstate cancer; Laparoscopy; Surgical margins; ContinenceProstatic NeoplasmLaparoscopyPositive Surgical MarginNeoplasm Recurrence LocalbusinessFollow-Up StudiesHuman
researchProduct

Intravesical bleomycin in bladder tumour prophylaxis.

1986

The authors have evaluated the efficacy, tolerability and systemic absorption of bleomycin administered by intravesical route in the prophylaxis of recurrences of superficial vesical tumours after endoscopic resection (TUR). Thirty mg of bleomycin dissolved in 30 ml of saline solution were instilled in the bladder once a week for the first month and then once a month for 12 months. The instilled fluid was held in the bladder for 1 hour. The systemic absorption of the drug was evaluated by a microbiological assay of bleomycin in plasma and in the perfusion liquid recovered from the bladder. Fifteen patients were treated; most had a long history of multiple recurrent tumours despite previous …

NephrologyMalemedicine.medical_specialtyContact timeUrologymedicine.medical_treatmentBleomycinchemistry.chemical_compoundBleomycinInternal medicinemedicineIntravesical routeHumansSalineAgedCarcinoma Transitional Cellbusiness.industryMiddle AgedSurgeryTolerabilitychemistryUrinary Bladder NeoplasmsNephrologyToxicityFemaleNeoplasm Recurrence LocalbusinessPerfusionInternational urology and nephrology
researchProduct

Huge isolated port-site recurrence after laparoscopic partial nephrectomy: a case report.

2009

A 66-yr-old man with pain and swelling in the right flank was referred to our clinic for diagnosis. In 2005, the patient underwent a laparoscopic partial nephrectomy for renal cancer of the lower pole of the right kidney. A computed tomography scan revealed a 20-cm tumor in the right abdominal wall, resulting in a suspected diagnosis of port-site metastasis from the first laparoscopic operation. The patient underwent open surgery, which confirmed the diagnosis. After the operation, the patient recovered rapidly.

NephrologyMalemedicine.medical_specialtyUrologymedicine.medical_treatmentNephrectomySettore MED/24 - UrologiaMetastasisLaparoscopynephrectomy recurrenceAbdominal wallNeoplasm SeedingInternal medicinePort-site metastasismedicineHumansLaparoscopyKidney cancer; Laparoscopy; Port-site metastasisCarcinoma Renal CellAgedmedicine.diagnostic_testbusiness.industryAbdominal WallKidney cancermedicine.diseaseNephrectomyKidney NeoplasmsSurgeryEndoscopymedicine.anatomical_structureLaparoscopybusinessKidney cancerKidney diseaseEuropean urology
researchProduct

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

2018

PURPOSE: To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. METHODS: According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. RESULTS: Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors > 3 cm or with CIS had earlier cystectomies (HR = 1…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyKaplan-Meier EstimateSettore MED/24 - UrologiaCohort Studies0302 clinical medicineRetrospective StudieMultivariate AnalysiOutcomeeducation.field_of_studyHigh riskBladder cancerMiddle AgedPrognosisEditorialTreatment OutcomeLocal030220 oncology & carcinogenesisBCG VaccineFemaleSurvival AnalysiBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; UrologyHumanmedicine.medical_specialtyPrognosiUrologyPopulationUrologyOutcomesT1G3CystectomyRisk AssessmentDisease-Free SurvivalCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansNeoplasm InvasivenesseducationSurvival analysisProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingNeoplasm InvasiveneCarcinoma Transitional CellBladder cancerbusiness.industryProportional hazards modelBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; Aged; BCG Vaccine; Carcinoma Transitional Cell; Cohort Studies; Cystectomy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder NeoplasmsCarcinomaRetrospective cohort studymedicine.diseaseSurvival AnalysisNeoplasm RecurrenceUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisProportional Hazards ModelTransitional CellCohort StudieNeoplasm Recurrence LocalbusinessExtravesical disease
researchProduct

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as pr…

2018

PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (7…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyNon-muscle invasive bladder cancer · Re-transurethral resection of the bladder · Recurrence · ProgressionSettore MED/24 - Urologia0302 clinical medicineRetrospective StudieRe-transurethral resection of the bladderRecurrenceImmunologicCause of DeathCumulative incidenceStage (cooking)Cause of deathProgressionIntravesicalAdministration IntravesicalLocal030220 oncology & carcinogenesisAdministrationBCG VaccineDisease ProgressionFemaleNon-muscle invasive bladder cancerHumanReoperationmedicine.medical_specialtyUrologyUrologyCystectomyArticleFollow-Up StudieCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansAdjuvantsAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesBladder cancerProportional hazards modelbusiness.industryNon-muscle invasive bladder cancer; Progression; Re-transurethral resection of the bladder; Recurrence; Adjuvants Immunologic; Administration Intravesical; Aged; BCG Vaccine; Cause of Death; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence Local; Neoplasm Staging; Proportional Hazards Models; Reoperation; Retrospective Studies; Urinary Bladder NeoplasmsRetrospective cohort studymedicine.diseaseNeoplasm RecurrenceUrinary Bladder NeoplasmsProportional Hazards ModelNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-al…

1993

A total of 62 patients at high risk for recurrence of superficial bladder cancer were selected for a study designed to compare the prophylactic efficacy of different doses and schedules of sequential intravesical instillations of epirubicin and interferon-alpha-2b and to evaluate which sequence could enhance the release of cytokines in the urine. Our investigations showed a significant increase in urinary concentrations of interleukins in patients who received the sequential intravesical administration of epirubicin and interferon-alpha-2b. Higher urinary concentrations of interleukins and a lower recurrence rate were detected in patients who received interferon-alpha-2b 24 h after epirubic…

Nephrologymedicine.medical_specialtyUrologyUrinary systemUrologyAlpha interferonIntravesical immunotherapyUrineInterferon alpha-2PharmacologyDrug Administration ScheduleIntravesical chemotherapyInterferon-alpha-2bSettore MED/24 - UrologiaInternal medicinemedicineHumansCombined Modality TherapyEpirubicinbusiness.industryInterleukinsInterferon-alphaInterleukinCombined Modality TherapyRecombinant ProteinsClinical trialInterleukins (urinary concentration of)Administration IntravesicalUrinary Bladder NeoplasmsInterleukin-2Interleukin-4Neoplasm Recurrence LocalbusinessInterleukin-1Epirubicinmedicine.drugUrological Research
researchProduct

Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis

2014

Background: Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal. Aim: We performed a meta-analysis of published studies, with the aim of estimating the 1-year rates of survival, analysing the variability in survival rates and, finally, identifying the factors associated with a longer survival. Methods: Data from 8 of the 17 selected studies were pooled, while the other 9 were excluded because survival rates were missing. All included studies were retrospective. Results: Overall, the 1-year survival ranged from 18% to 90%. Tumour progression was the main cause of death. The second cause was bleeding, reported only in pat…

NiacinamidePhenylurea CompoundOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomamedicine.medical_treatmentAntineoplastic AgentsLiver transplantationAntineoplastic AgentRecurrenceInternal medicinemedicineHumansIn patientPostoperative PeriodProspective cohort studyLiver transplantSurvival rateCause of deathHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsGastroenterologySorafenibmedicine.diseaseLiver TransplantationSurvival RateReceptors Vascular Endothelial Growth FactorLiver NeoplasmHepatocellular carcinomaMeta-analysisNeoplasm Recurrence LocalbusinessHumanmedicine.drugDigestive and Liver Disease
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct

Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant …

2020

Although liver transplantation (LT) is the best treatment for patients with localized hepatocellular carcinoma (HCC), recurrence occurs in 6%-18% of patients. Several factors, particularly morphological criteria combined with dynamic parameters, known before LT modify this risk and combined in prediction models may be used to stratify patients at need of variable surveillance strategies. Additional variables though likely explain differences in recurrence rates in patients with the same pre-LT HCC status. One of these variables is possibly immunosuppression (IS). Once recurrence takes place, management is highly heterogenous. Within the International Liver Transplantation Society Consensus …

OncologyAblation Techniquesmedicine.medical_specialtyCarcinoma HepatocellularConsensusmedicine.medical_treatmentConsensus Development Conferences as TopicMEDLINE030230 surgeryLiver transplantationMedical OncologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansIn patientGrading (tumors)Societies MedicalPostoperative CareTransplantationbusiness.industryLiver NeoplasmsConsensus conferenceImmunosuppressionChemoradiotherapy Adjuvantmedicine.diseasePrognosisUnited StatesLiver TransplantationQuality of evidenceEuropeTreatment OutcomeHepatocellular carcinomaPractice Guidelines as Topic030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Local and Regional Therapies for Hepatocellular Carcinoma.

2020

OncologyAblation Techniquesmedicine.medical_specialtyCarcinoma HepatocellularHepatologybusiness.industryLiver NeoplasmsMEDLINEmedicine.diseaseLiver TransplantationText miningHepatocellular carcinomaInternal medicineMedicineHumansChemoembolization TherapeuticNeoplasm Recurrence LocalbusinessHepatology (Baltimore, Md.)References
researchProduct